Literature DB >> 24694535

T-cell receptor transfer into human T cells with ecotropic retroviral vectors.

L Koste1, T Beissert2, H Hoff2, L Pretsch1, Ö Türeci1, U Sahin3.   

Abstract

Adoptive T-cell transfer for cancer immunotherapy requires genetic modification of T cells with recombinant T-cell receptors (TCRs). Amphotropic retroviral vectors (RVs) used for TCR transduction for this purpose are considered safe in principle. Despite this, TCR-coding and packaging vectors could theoretically recombine to produce replication competent vectors (RCVs), and transduced T-cell preparations must be proven free of RCV. To eliminate the need for RCV testing, we transduced human T cells with ecotropic RVs so potential RCV would be non-infectious for human cells. We show that transfection of synthetic messenger RNA encoding murine cationic amino-acid transporter 1 (mCAT-1), the receptor for murine retroviruses, enables efficient transient ecotropic transduction of human T cells. mCAT-1-dependent transduction was more efficient than amphotropic transduction performed in parallel, and preferentially targeted naive T cells. Moreover, we demonstrate that ecotropic TCR transduction results in antigen-specific restimulation of primary human T cells. Thus, ecotropic RVs represent a versatile, safe and potent tool to prepare T cells for the adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24694535     DOI: 10.1038/gt.2014.25

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  3 in total

1.  Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening.

Authors:  Alexandra G Orlandini von Niessen; Marco A Poleganov; Corina Rechner; Arianne Plaschke; Lena M Kranz; Stephanie Fesser; Mustafa Diken; Martin Löwer; Britta Vallazza; Tim Beissert; Valesca Bukur; Andreas N Kuhn; Özlem Türeci; Ugur Sahin
Journal:  Mol Ther       Date:  2018-12-18       Impact factor: 11.454

2.  A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity.

Authors:  Tim Beissert; Mario Perkovic; Annette Vogel; Stephanie Erbar; Kerstin C Walzer; Tina Hempel; Silke Brill; Erik Haefner; René Becker; Özlem Türeci; Ugur Sahin
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

3.  Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.

Authors:  Stefan Hutzler; Stephanie Erbar; Robert A Jabulowsky; Jan R H Hanauer; Jürgen H Schnotz; Tim Beissert; Bianca S Bodmer; Regina Eberle; Klaus Boller; Thorsten Klamp; Ugur Sahin; Michael D Mühlebach
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.